Enjoy complimentary customisation on priority with our Enterprise License!
The pulmonary edema therapeutics market size is forecast to increase by USD 365.5 million at a CAGR of 3.27% between 2023 and 2028. The market is witnessing significant growth due to the high prevalence of risk factors such as heart failure, lung diseases, and respiratory distress. The increasing use of biomarkers for disease diagnosis is also driving market growth, as these markers enable early detection and timely intervention. However, the market faces challenges due to the adverse effects of available therapeutics, including hypotension, arrhythmias, and renal dysfunction. Additionally, the high cost of these therapies and the lack of effective long-term management strategies are hindering market growth. To address these challenges, there is a growing focus on developing novel therapeutic approaches, such as gene therapy and stem cell therapy, which offer promising benefits with minimal side effects. Overall, the market is expected to grow steadily over the forecast period, driven by the increasing burden of associated diseases and the development of more effective and safer treatment options.
Pulmonary edema is a serious complication of heart failure, characterized by the accumulation of fluid in the lungs. Heart treatments for pulmonary edema aim to reduce the workload on the heart, improve cardiac output, and manage fluid build-up in the lungs. The geriatric population is at a higher risk due to age-related cardiovascular changes and prevalence of heart failure. The treatment for acute and chronic pulmonary edema includes supplemental oxygen, medicines like ACE inhibitors, ARBs, diuretics, and inotropic agents. Biomarkers such as BNP and NT-proBNP are used for diagnostic evaluations to assess the biological state of heart failure and disease progression.
Further, hypertensive crisis, intra-ventricular septum displacement, and pulmonary shunt are common complications of heart failure leading to pulmonary edema. Cardiac issues like cardiac tamponade, valvular disease, and myocardial infarction can also cause pulmonary edema. Lung parenchyma damage and breathing difficulties are common symptoms. Prognosis depends on the underlying cause, timely diagnosis, and response to treatment. The National Heart, Lung, and Blood Institute and the American College of Chest Physicians provide guidelines for managing pulmonary edema.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The cardiogenic pulmonary edema segment is estimated to witness significant growth during the forecast period. Pulmonary edema is a disorder characterized by an abnormal accumulation of fluid in the lungs, leading to impaired breathing and cardiac issues. The largest segment of the market is cardiogenic pulmonary edema, which arises from heart failure due to cardiac output reduction. This condition occurs when the left ventricle, the heart's main pumping chamber, is unable to eject sufficient blood, resulting in increased pressure within the heart. The ensuing pressure wave in the left atrium propagates to the lungs' veins and capillaries, causing fluid to leak into the lung parenchyma and air sacs. Heart failure, primarily in the geriatric population, is a significant risk factor for pulmonary edema.
The National Heart, Lung and Blood Institute's studies, such as the ARIC and CHS, have identified this issue as a critical health concern. Cardiovascular failure, including hypertensive crisis and pulmonary shunt, can also lead to pulmonary edema. Treatment for pulmonary edema includes cardiac medications like LASIX, EDECRIN, ALDACTONE, and NITROPRESS. These drugs help manage the symptoms by reducing fluid buildup in the lungs and improving heart function. Other therapeutic interventions include supplemental oxygen, biomarker-guided diagnosis, and diagnostic evaluations. The market is dynamic, with ongoing developments in disease control through joint ventures, acquisitions, mergers, and collaborations. The market caters to various channels, including retail pharmacies, hospital pharmacies, and online pharmacies, to ensure easy access to essential medicines for patients. Respiratory syndrome coronavirus and other acute or chronic conditions may also impact the market's growth and prognosis.
Get a glance at the market share of various segments Request Free Sample
The cardiogenic pulmonary edema segment was valued at USD 1.33 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market encompasses various heart treatments for individuals suffering from heart failure, particularly in the geriatric population. Heart failure, a condition characterized by cardiovascular failure, results in the inability of the heart to pump blood effectively, leading to fluid accumulation in the lungs, known as pulmonary edema. This disorder can be caused by various factors, including hypertensive crisis, intra-ventricular septum defects, and respiratory syndrome coronavirus. Pulmonary edema is marked by symptoms such as shortness of breath, rapid breathing, and coughing up pink or white frothy sputum. Diagnostic evaluations, including arterial blood gas analysis, can help distinguish between cardiogenic and non-cardiogenic pulmonary edema.
Further, treatment options range from supplemental oxygen and medicines to invasive procedures like pulmonary shunts. The National Heart, Lung and Blood Institute's studies, such as the ARIC and CHS, have contributed significantly to understanding the biological state of pulmonary edema. Retail pharmacies, hospital pharmacies, and online pharmacies play a crucial role in providing access to necessary medicines for managing this condition. Disease Control, through joint ventures, acquisitions, and mergers, continues to invest in research and development for new therapies and biomarkers to improve patient prognosis.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The high prevalence of risk factors is the key driver of the market. Pulmonary edema is a life-threatening disease process characterized by the accumulation of fluid in the lungs, leading to difficulty in breathing. The disease can be caused by various factors, including infections, organ failures, and lifestyle habits. Infections, such as bacterial, viral, fungal, and Respiratory Syncytial Virus (RSV), are the most common causes of pulmonary edema. These infections result from the damage to the capillary endothelium, leading to the leakage of fluid and protein into the lung interstitium. The high global prevalence of these infections contributes significantly to the growth of the market. For instance, RSV affects over 64 million people annually, resulting in approximately 160,000 deaths.
Moreover, clinical examination, imaging testing, and blood tests are essential for diagnosing pulmonary edema. Devices like ventilators are used for ventilator-assisted respiration in severe cases. Cardiac disorders, kidney disorders, and cardiovascular diseases, including carotid artery disease, cardiomyopathy, heart valve problems, hypertension, and coronary artery disease, are also risk factors for pulmonary edema. Healthcare systems, healthcare investments, and infrastructure play a crucial role in the supply chain of pharmaceutical products, including drugs and vaccines, used for treating pulmonary edema. The therapeutic areas of immunology, oncology, cardiology, endocrinology, and neurology are major contributors to the development of new therapeutics for pulmonary edema. The portfolio of pharmaceutical products includes a wide range of drugs and vaccines, which are distributed through wholesalers, retailers, hospitals, clinics, and pharmacies.
Increasing use of biomarkers for disease diagnosis is the upcoming trend in the market. Pulmonary edema is a disease process characterized by the accumulation of fluid in the lungs, leading to shortness of breath and other respiratory symptoms. Clinical examination and imaging testing are the primary methods for diagnosing pulmonary edema. Imaging tests, such as chest X-rays and echocardiograms, can reveal signs of fluid buildup in the lungs and an enlarged heart. Clinical evaluation may also include blood tests to detect biomarkers indicative of heart failure, such as brain natriuretic peptide (BNP) or N-terminal-pro BNP (NT-pro-BNP). These cardiac markers are elevated when the heart is not pumping effectively, leading to pulmonary edema. Cardiovascular diseases, including cardiac disorders like heart failure, cardiomyopathy, heart valve problems, hypertension, and carotid artery disease, can cause pulmonary edema.
Further, kidney disorders, infections, and ventilator-assisted respiration can also contribute to the disease. Healthcare systems invest heavily in infrastructure and health care to diagnose and treat pulmonary edema, including devices, drugs, vaccines, and medical disciplines such as immunology, oncology, cardiology, endocrinology, and neurology. The pharmaceutical industry's portfolio includes therapeutic areas targeting pulmonary edema, such as diuretics, vasodilators, and inotropes. The supply chain for pulmonary edema therapeutics involves wholesalers, retailers, hospitals, clinics, and pharmacies. Blood vessel walls' damage from conditions like coronary artery disease and high blood pressure can lead to pulmonary edema. Effective diagnosis and treatment are crucial to prevent complications and improve patient outcomes.
Adverse effects of available therapeutics is a key challenge affecting the market growth. The market encompasses a range of drugs and devices used in the treatment of various cardiovascular diseases, including cardiac disorders such as heart failure, cardiomyopathy, heart valve problems, and hypertension, as well as kidney disorders and infection-related pulmonary edema. Clinical examination, imaging testing, and blood tests are essential for diagnosing these conditions. The market includes pharmaceutical products from various therapeutic areas, including immunology, oncology, cardiology, endocrinology, and neurology. The use of pulmonary edema therapeutics is driven by the increasing prevalence of high-risk factors, such as congestive heart failure and kidney failure. However, the market faces challenges due to adverse effects associated with these drugs.
However. common side effects include headache, fever, chills, nausea, and vomiting, while more serious adverse effects include dehydration, which can lead to electrolyte imbalances. The US FDA has issued black box warnings for certain drugs, such as LASIX, due to these risks. The healthcare system plays a crucial role in the supply chain of pulmonary edema therapeutics, with wholesalers, retailers, hospitals, clinics, and pharmacies all contributing to the distribution and availability of these products. Healthcare investments and infrastructure are essential to ensuring access to these treatments for patients. In addition to drugs, therapeutic options include ventilator-assisted respiration and other devices used in the management of pulmonary edema.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc. - The company offers FIRAZYR which is a bradykinin B2 receptor antagonist indicated for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Pulmonary edema is a potentially life-threatening condition characterized by the accumulation of fluid in the lungs, leading to impaired breathing and cardiac issues. This disorder can occur due to various causes, including heart failure, hypertensive crisis, and respiratory syndrome coronavirus. The global heart treatments market for pulmonary edema is expected to grow significantly due to the increasing geriatric population, who are more susceptible to heart failure and cardiovascular disorders. Treatment for pulmonary edema includes medicines like ACE inhibitors, ARBs, and diuretics. In severe cases, invasive procedures such as intra-aortic balloon pumping and mechanical ventilation may be required. The National Heart, Lung and Blood Institute recommends regular disease control evaluations, including arterial blood gas analysis and diagnostic evaluations, to monitor the biological state of the patient.
Further, the market for pulmonary edema therapeutics is diverse, with retail pharmacies, hospital pharmacies, and online pharmacies being major distribution channels. Joint ventures, acquisitions, and mergers are common strategies adopted by key players to expand their market presence. Biomarkers play a crucial role in diagnosing and monitoring the progression of pulmonary edema. Supplemental oxygen and non-invasive positive pressure ventilation are also used to manage the symptoms. The prognosis for pulmonary edema depends on the underlying cause and timely intervention. Cardiogenic pulmonary edema, caused by heart failure, has a better prognosis compared to non-cardiogenic pulmonary edema. The lungs, as vital organs for breathing, are affected by the accumulation of fluid, leading to impaired gas exchange and breathing difficulties.
Market Scope |
|
Report Coverage |
Details |
Page number |
145 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 3.27% |
Market Growth 2024-2028 |
USD 365.5 million |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
3.13 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 41% |
Key countries |
US, Germany, UK, China, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., ADVANZ PHARMA, Apotex Inc., Bausch Health Companies Inc., Baxter International Inc., CHIESI Farmaceutici SpA, CMP Pharma Inc., Emcure Pharmaceuticals Ltd., Epic Pharma LLC, Fresenius Kabi AG, Hikma Pharmaceuticals Plc, Johnson and Johnson Services Inc., Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Teva Pharmaceutical Industries Ltd., Validus Pharmaceuticals LLC, and Viatris Inc. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.